KX01 is an oral agent that has a dual mechanism of action resulting in broad activity but selectively targets proteins that are involved in the growth and development of cancer. KX01 is being evaluated in a “Phase Ib Rising Multiple-Dose Clinical Study to Evaluate Safety, Tolerability, and Activity of Oral Monotherapy with KX2-391 in Elderly Subjects with Acute Myeloid Leukemia (AML) Who Are Refractory to or Have Declined Standard Induction Therapy.”
This study is being done at the following cancer research centers:
- Roswell Park Cancer Institute (Buffalo, NY)
- Thomas Jefferson University (Philadelphia, PA)
- Cornell University- Weill Medical College (New York, NY)
To inquire about participation in this study, contact the study coordinator at the site. Contact information can be found at clinicaltrials.gov.